{"id":3223133,"date":"2025-12-02T20:52:05","date_gmt":"2025-12-02T21:52:05","guid":{"rendered":"https:\/\/ur1stop.com\/blog\/?p=3223133"},"modified":"2025-12-02T22:32:09","modified_gmt":"2025-12-02T22:32:09","slug":"glp-1-drugs-may-reach-fewer-than-one-in-10-people-who-need-them-experts-predict","status":"publish","type":"post","link":"https:\/\/ur1stop.com\/blog\/2025\/12\/02\/glp-1-drugs-may-reach-fewer-than-one-in-10-people-who-need-them-experts-predict\/","title":{"rendered":"GLP-1 drugs may reach fewer than one in 10 people who need them, experts predict"},"content":{"rendered":"
\n

NEW<\/span>You can now listen to Fox News articles!\n <\/p>\n<\/div>\n

The World Health Organization (WHO) has announced its official guidance on the use of GLP-1 drugs<\/a> for treating obesity.<\/p>\n

GLP-1 drugs are medications that mimic the natural hormone glucagon-like peptide-1 (GLP-1), which are most commonly used for type 2 diabetes and medical weight loss.<\/p>\n

The first guideline, released on Dec. 1, aims to address the “growing global health challenge of obesity<\/a>,” WHO wrote in a press release.<\/p>\n

WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT<\/strong><\/a><\/p>\n

Obesity affects more than one billion people globally and was associated with 3.7 million deaths. The number of people with obesity is expected to double by 2030.<\/p>\n

While GLP-1 medications were added to the WHO\u2019s Essential Medicines List for managing type 2 diabetes<\/a> in high-risk groups in September 2025, the new guideline adds two key “conditional recommendations” for people with obesity.<\/p>\n

\n
\"The<\/picture>